Geyer, T.; Rübenthaler, J.; Alunni-Fabbroni, M.; Schinner, R.; Weber, S.; Mayerle, J.; Schiffer, E.; Höckner, S.; Malfertheiner, P.; Ricke, J.
NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial. Cancers 2021, 13, 2787.
https://doi.org/10.3390/cancers13112787
AMA Style
Geyer T, Rübenthaler J, Alunni-Fabbroni M, Schinner R, Weber S, Mayerle J, Schiffer E, Höckner S, Malfertheiner P, Ricke J.
NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial. Cancers. 2021; 13(11):2787.
https://doi.org/10.3390/cancers13112787
Chicago/Turabian Style
Geyer, Thomas, Johannes Rübenthaler, Marianna Alunni-Fabbroni, Regina Schinner, Sabine Weber, Julia Mayerle, Eric Schiffer, Sebastian Höckner, Peter Malfertheiner, and Jens Ricke.
2021. "NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial" Cancers 13, no. 11: 2787.
https://doi.org/10.3390/cancers13112787
APA Style
Geyer, T., Rübenthaler, J., Alunni-Fabbroni, M., Schinner, R., Weber, S., Mayerle, J., Schiffer, E., Höckner, S., Malfertheiner, P., & Ricke, J.
(2021). NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial. Cancers, 13(11), 2787.
https://doi.org/10.3390/cancers13112787